#Novo Holdings #Denmark #Copenhagen #Britt Meelby Jensen #Lars Green

Novo Holdings Revolutionizes Its Board Leadership

Copenhagen, Denmark – In a pivotal shift that reflects its strategic vision for the future, Novo Holdings has announced plans to elect Lars Green, the former CFO of Novozymes (now known as Novonesis), as the new Chair of its Board of Directors. Alongside him, Britt Meelby Jensen, the current CEO of Ambu, will take on the role of Vice Chair, succeeding Steen Riisgaard, who has held this position since 2018.

Lars Rebien Sørensen, who has been the Chair since 2018, will step down to focus on his role at Novo Nordisk A/S, as recently proposed by the Novo Nordisk Foundation. Sørensen’s leadership has been instrumental during his tenure at Novo Holdings, steering the company towards substantial achievements.

With over three decades of experience in the healthcare and life sciences sectors, Lars Green has a proven track record. After joining Novo Nordisk in 1992, he ascended through various financial leadership roles, including positions in Japan and North America. His strategic insights culminated in his role as CFO at Novozymes until the end of 2023, demonstrating his adept management skills in navigating complex financial landscapes.

Britt Meelby Jensen, celebrated as 'Leader of the Year' by Denmark’s foremost leadership organization in 2024, brings with her extensive industry experience. Since joining the Board of Novo Holdings in 2022, Jensen has played a vital role in guiding the company’s strategic directives. As Vice Chair, she is positioned to enhance board initiatives, and her leadership style aligns with the innovative aspirations of Novo Holdings.

The upcoming leadership changes have been met with optimism by existing board members and stakeholders. Lars Rebien Sørensen commended the incoming leaders, stating, “Lars and Britt are already well-acquainted with the operations of Novo Holdings. Their expertise will significantly contribute to the sustained growth of the organization in its quest to become a frontrunner in global life science investment.”

Lars Green expressed enthusiasm about his new responsibilities, stating, “I eagerly anticipate leading the board and collaborating closely with the management team to drive forward Novo Holdings’ mission. Our objective is to secure attractive returns that empower the Novo Nordisk Foundation in its charitable endeavors aimed at improving lives globally and fortifying our planet.”

Also noteworthy is the resignation of Henrik Poulsen, who will exit the Board in tandem with his departure from Novo Nordisk. His contributions have been vital in the dual roles he played in both companies.

These changes are more than just a transition of roles; they are part of a broader strategy to maintain and enhance Novo Holdings' stature in investment and innovation within the life sciences sector. The adjustments to the Board are set to take effect in November 2025, and stakeholders await to see how these new appointments will further propel the organization’s goals.

As Nova Holdings stands at the precipice of this new chapter, the changes reflect its commitment to fostering robust leadership capable of navigating the complexities of the global healthcare environment. As the organization continues to pursue outstanding investment opportunities, the newly appointed Chair and Vice Chair are expected to steer the company toward sustained growth and impactful philanthropic efforts through the Novo Nordisk Foundation.